AVXL
Anavex Life Sciences Corp
2.40$
+1.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 100.0% | 100.0% | 99.4% | 99.8% | 99.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.8% | 98.8% | 96.7% | 98.6% | 94.1% | 87.6% | 84.7% | 94.1% | 97.7% | 97.8% | 97.5% | 98.8% | |
| 98.8% | 98.8% | 96.7% | 98.6% | 94.1% | 87.6% | 84.7% | 94.1% | 97.7% | 97.8% | 97.5% | 98.8% | |
| 1.0% | 0.5% | 0.8% | 0.0% | 7.7% | 10.4% | 14.0% | 5.7% | 2.1% | 1.8% | 1.8% | 0.8% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -10.4% | – | 0.0% | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 97.4% | 17.2% | 33.6% | 12.9% | 15.9% | 19.9% | 21.1% | 6.7% | 6.7% | 8.1% | 11.3% | 8.6% | |
| 19.6% | 17.2% | 33.6% | 12.9% | 15.9% | 19.9% | 21.1% | 6.7% | 6.7% | 8.1% | 11.3% | 8.6% | |
| 2.6% | 0.6% | – | – | – | – | – | – | – | – | – | – | |
| 16.6% | 16.0% | 32.2% | 12.9% | 12.1% | 13.9% | 11.5% | 2.9% | 2.5% | 2.8% | 7.1% | 4.1% | |
| 3.6% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | |
| 2.6% | 82.8% | 66.4% | 87.1% | 84.1% | 80.1% | 78.9% | 93.3% | 93.3% | 91.9% | 88.7% | 91.4% | |
| -714.9% | -409.1% | -821.4% | -328.6% | -446.9% | -526.6% | -462.3% | -122.3% | -160.8% | -189.8% | -247.9% | -368.4% | |
| 133.3% | 120.1% | 370.1% | 146.7% | 183.2% | 193.1% | 168.5% | 43.2% | 50.4% | 51.7% | 61.6% | 82.2% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.